During the past decade, Office of George Timothy Kelly, MD conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 4 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Office of George Timothy Kelly, MD" are "Rheumatoid Arthritis" (3 trials) and "Lupus Erythematosus, Systemic" (1 trials). Many other conditions were trialed in "Office of George Timothy Kelly, MD" in a lesser frequency.

Most popular intervention types in "Office of George Timothy Kelly, MD" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Baricitinib" (2 trials), "Placebo" (2 trials), "Acthar Gel" (1 trials), "Adalimumab" (1 trials) and "Adalimumab Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Office of George Timothy Kelly, MD" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Office of George Timothy Kelly, MD". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Office of George Timothy Kelly, MD, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Office of George Timothy Kelly, MD, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".